Thermo Fisher Scientific(TMO)
Thermo Fisher Scientific (Waltham MA; NYSE: TMO; ~$43B revenue 2024) is the world's largest manufacturer of cell culture media through its Gibco brand — the dominant label in CHO (Chinese Hamster Ovary) cell culture media for biopharmaceutical manufacturing. Gibco CHO-S Serum-Free Medium, GlutaMAX supplement, CD CHO medium, and EX-CELL Advanced CHO media series supply the majority of global monoclonal antibody manufacturing processes. Thermo Fisher's cell culture media is manufactured primarily at its Grand Island, NY facility (acquired from Life Technologies, itself formerly GIBCO BRL), which is the single most important cell culture media manufacturing site in North America. Thermo Fisher also operates a major media production site in Paisley, Scotland (UK) that serves European biopharmaceutical manufacturing. Gibco media formulations are validated into more FDA-approved biologics manufacturing processes than any other supplier — creating regulatory lock-in equivalent to Cytiva's position in chromatography resins. The 2014 Thermo Fisher merger with Life Technologies (which itself had acquired Invitrogen in 2008 and GIBCO BRL in 2000) consolidated what were once multiple competing cell culture brands into a single dominant supplier.